0001209191-17-058480.txt : 20171031 0001209191-17-058480.hdr.sgml : 20171031 20171031181642 ACCESSION NUMBER: 0001209191-17-058480 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171027 FILED AS OF DATE: 20171031 DATE AS OF CHANGE: 20171031 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 171166871 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-27 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP\Chief Commercial Officer Common Stock 2017-10-27 4 S 0 4165 141.41 D 116952 D Common Stock 2017-10-27 4 M 0 2125 96.87 A 119077 D Common Stock 2017-10-27 4 S 0 2125 149.00 D 116952 D Common Stock 2017-10-31 4 S 0 11617 142.18 D 105335 D Common Stock 2017-10-31 4 S 0 5600 143.54 D 99735 D Common Stock 2017-10-31 4 S 0 25999 144.54 D 73736 D Common Stock 2017-10-31 4 S 0 17501 145.34 D 56235 D Common Stock 2017-10-31 4 S 0 7783 146.61 D 48452 D Common Stock 2017-10-31 4 S 0 5000 147.87 D 43452 D Common Stock 2017-10-31 4 S 0 1000 148.54 D 42452 D Common Stock 2017-10-31 4 S 0 500 149.34 D 41952 D Common Stock 140 I 401(k) Stock Option (Right to Buy) 96.87 2017-10-27 4 M 0 2125 0.00 D 2024-07-14 Common Stock 2125 6375 D Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $142.18 (range $141.83 to $142.74). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $143.54 (range $143.03 to $144.02). Open market sales reported on this line occurred at a weighted average price of $144.54 (range $144.04 to $145.01). Open market sales reported on this line occurred at a weighted average price of $145.34 (range $145.05 to $145.87). Open market sales reported on this line occurred at a weighted average price of $146.61 (range $146.20 to $147.18). Open market sales reported on this line occurred at a weighted average price of $147.87 (range $147.22 to $148.20). Open market sales reported on this line occurred at a weighted average price of $148.54 (range $148.25 to $149.18). The option vests in 16 quarterly installments from 7/15/2014. /s/ Omar White, Attorney-in-Fact 2017-10-31